US Patent No. 10,428,070

HEPATITIS B ANTIVIRAL AGENTS


Patent No. 10,428,070
Issue Date October 01, 2019
Title Hepatitis B Antiviral Agents
Inventorship Yao-Ling Qiu, Andover, MA (US)
Xuri Gao, Newtonville, MA (US)
Xiaowen Peng, Sudbury, MA (US)
Wei Li, Lexington, MA (US)
Jorden Kass, Arlington, MA (US)
Hui Cao, Belmont, MA (US)
Byung-Chul Suh, Lexington, MA (US)
Yat Sun Or, Waltham, MA (US)
Assignee Enanta Pharmaceuticals, Inc., Watertown, MA (US)

Claim of US Patent No. 10,428,070

1. A compound represented by Formula (I):or a pharmaceutically acceptable salt thereof, wherein:A is optionally substituted aryl or optionally substituted heteroaryl;
B is selected from the group consisting of hydrogen, halo, CN, optionally substituted —C1-C6 alkyl, and optionally substituted C3-C6 cycloalkyl;
X is optionally substituted aryl or optionally substituted heteroaryl;
Y is —C(O)NR1R2, —C(O)OR1, optionally substituted aryl or optionally substituted heteroaryl;
R1 and R2 are each independently selected from the group consisting of hydrogen, optionally substituted —C1-C6 alkyl, optionally substituted —C2-C8 alkenyl, optionally substituted —C2-C8 alkynyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; alternatively, R1 and R2 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic; and
R and Z are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, or 3- to 8-membered heterocyclic;
provided that when Y is optionally substituted aryl or optionally substituted heteroaryl, R and Z taken together with carbon atom to which they are attached do not form
where R5 is hydrogen, optionally substituted —C1-C8 alkyl, optionally substituted —C2-C8 alkenyl, optionally substituted —C2-C8 alkynyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)R13, —C(O)OR13, —C(O)NR13R14, —S(O)2R13, or —S(O)2NR13R14; and R13 and R14 at each occurrence are independently hydrogen, optionally substituted —C1-C8 alkyl, optionally substituted —C2-C8 alkenyl, optionally substituted —C2-C8 alkynyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl or optionally substituted heteroaryl.